裴俊平，博士，讲师，硕士研究生导师，暨南大学“青蓝学者”。男，2022年博士毕业于四川大学生物治疗国家重点实验室，同年在中国科学院上海药物所进行博士后研究，2024年加入暨南大学药学院工作。

        聚焦靶向抗肿瘤药物发现，通过合理药物设计并合成先导化合物，通过化学生物学等方法进行作用机制研究，为创新药物发现提供基础。担任广东省药物化学专业委员会副秘书长，担任Eur. J. Med. Chem等杂志的审稿人。主要工作发表论文20多篇，其中以（共同）第一和通讯作者在J Med Chem，J Hematol Oncol，Acta Pharm Sin B，Chem. Commun，Org Lett等高水平学术期刊发表论文13篇。迄今主持国家自然科学基金青年项目1项、省部级项目2项，中央高校基本科研业务费项目1项。参加国家重点研发项目2项。

讲授课程：

        药物化学、药物化学实验、有机化学实验

研究方向：

        1、靶向药物设计、合成与先导化合物优化研究

        2、靶向蛋白降解技术（尤其是分子胶降解剂与PROTACs）

代表性科研项目：

        1、国家自然科学基金青年科学基金项目（C类）（82504569，主持）

        2、广东省自然科学基金面上项目（2026A1515012332，主持）

        3、山东省自然科学基金青年项目（ZR2023QH355，主持）

        4、中央高校基本科研业务费项目（21625351，主持）

代表性论文：

        [1] Pei, J.#; Wang, G.#; Wang, A.#; Wu, C.; Pan, X.; Shuai, W.; Bu, F.; Zhu, Y.; Wang, Y.*; Ouyang, L.*; Li, W.* Design, Synthesis, and Antitumor Activity of Potent and Selective EGFR L858R/T790M Inhibitors and Identification of a Combination Therapy to Overcome Acquired Resistance in Models of Non-small-cell Lung Cancer. J Med Chem 2023, 66, 5719-5752. (IF = 6.8)

        [2] Wang, A.#; Shuai, W.#; Wu, C.#; Pei, J.#; Yang, P.; Wang, X.; Li, S.; Liu, J.; Wang, Y.*; Wang, G.*; Ouyang, L.* Design, Synthesis, and Biological Evaluation of Dual Inhibitors of EGFR(L858R/T790M)/ACK1 to Overcome Osimertinib Resistance in Nonsmall Cell Lung Cancers. J Med Chem 2024, 67, 2777-2801. (IF = 6.8)

        [3] Pan, X.#; Pei, J.#; Wang, A.#; Shuai, W.; Feng, L.; Bu, F.; Zhu, Y.; Zhang, L.*; Wang, G.*; Ouyang, L.* Development of small molecule extracellular signal-regulated kinases (ERKs) inhibitors for cancer therapy. Acta Pharm Sin B 2022, 12, 2171-2192. (IF = 14.6)

        [4] Shi, K.#; Wang, G.#; Pei, J.#; Zhang, J.; Wang, J.; Ouyang, L.*; Wang, Y.*; Li, W.* Emerging strategies to overcome resistance to third-generation EGFR inhibitors. J Hematol Oncol 2022, 15, 94. (IF = 40.4)

        [5] Pei, J.#; Wang, G.#; Feng, L.; Zhang, J.; Jiang, T.; Sun, Q.*; Ouyang, L.* Targeting Lysosomal Degradation Pathways: New Strategies and Techniques for Drug Discovery. J Med Chem 2021, 64, 3493-3507. (IF = 6.8)

        [6] Wang, A.#; Pei, J.#; Shuai, W.#; Lin, C.; Feng, L.; Wang, Y.; Lin, F.*; Ouyang, L.*; Wang, G.* Small Molecules Targeting Activated Cdc42-Associated Kinase 1 (ACK1/TNK2) for the Treatment of Cancers. J Med Chem 2021, 64, 16328-16348. (IF = 6.8)

        [7] Pei, J.#; Pan, X.#; Wang, A.#; Shuai, W.; Bu, F.; Tang, P.; Zhang, S.; Zhang, Y.; Wang, G.*; Ouyang, L.* Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy. Chem Commun 2021, 57, 13194-13197. (IF = 4.2)

        [8] Pei, J.#; Wang, Y.; Shi, S.; Chen, L.; Yin, J.; Nan, F.* Synthesis and Biological Activity of Tetracyclic Dispiro Core Derivatives of Natural Products Dispirocochlearoids A-C. Org Lett 2024. 26, 9654-9658. (IF = 5.0)

        [9] Zhu, W.#; Pei, J.*; Lu, X.* A patent review of small molecular inhibitors targeting EGFR exon 20 insertion (Ex20ins) (2019-present). Expert Opin Ther Pat 2025, 35, 91-110. (IF = 4.6)

        [10] Wang, Q.#; Zhu, Y.; Pei, J.* Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors. Future Med Chem 2024, 16, 1923-1944. (IF = 3.4)

        [11] Jia, P.#; Pei, J.#; Wang, G.#; Pan, X.; Zhu, Y.; Wu, Y.*; Ouyang, L.* The roles of computer-aided drug synthesis in drug development. Green Synth Catal 2022, 3, 11-24. (IF = 6.3)

        [12] Pei, J.-P.#; Lv, X.-J.; Peng, C.-J.; Liu, Y.-K.* Asymmetric organocatalytic multicomponent reactions for efficient construction of bicyclic compounds bearing bisacetal and isoxazolidine moieties. Chem Commun 2020, 56, 12765-12768. (IF = 4.2)

        [13] Pei, J.-P.#; Chen, Y.-H.; Liu, Y.-K.* Asymmetric Organocatalytic Sequential Reaction of Structurally Complex Cyclic Hemiacetals and Functionalized Nitro-olefins To Synthesize Diverse Heterocycles. Org Lett 2018, 20, 3609-3612. (IF = 5.0)

学术兼职：

        广东省药物化学专业委员会副秘书长

联系方式：

        地址：广州市番禺区新造镇兴业大道东855号暨南大学药学院F2栋517

        邮箱：jppei@jnu.edu.cn